April 30th 2025
Infection was a leading cause of death in lower-risk myelodysplastic syndromes (MDS), highlighting the need for vigilant monitoring and preventive strategies.
Researchers Develop Improved Flow Cytometric Score for MDS Diagnosis
Analysis Reveals High Cost of Discontinued HMA Treatment for MDS
Heterogenous Nature of MDS Warrants Further Research, Review Finds
For Patients With HMA-Resistant MDS, What Are Their Options?
Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS